Further details about the 17th International Conference on Pharmaceutical Medicine (ICPM 2014) have been unveiled.
Further details about the 17th International Conference on Pharmaceutical Medicine (ICPM 2014) have been unveiled.
The congress is jointly organized by the International Federation of Associations of Pharmaceutical Physicians & Pharmaceutical Medicine (IFAPP) and the German Society of Pharmaceutical Medicine (Deutsche Gesellschaft für Pharmazeutische Medizin e.V.’ – DGPharMed).
“Drug development aiming for true innovations has become even more challenging in the past decade. The investments needed further increased, hurdles for approval and reimbursement became more demanding. In a globalized environment all economic regions are directly competing for R&D leadership in drug development,” noted the organizers, adding that the Berlin meeting will focus on the major framework conditions in that field.
The motto of the event is “The World Is Our Partner”. Beyond assessment of the status quo, the presentations will provide participants with an outlook on what it will take to stay on top of drug development. Experts will address the key topics relevant for smart development of better drugs, and there will also be exchange and networking with peers to discuss presentations and new topics.
To read the full release click here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.